Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Medical Device

A Talk With Beckman Coulter CEO Scott Garrett, New Chair Of AdvaMed Dx

This article was originally published in The Gray Sheet

  • News

Executive Summary

After years of debating whether to form their own trade association or stay under the big tent with the device industry's leading advocacy group, AdvaMed, diagnostics companies may now have the best of both worlds, says Scott Garrett

You may also be interested in...



Beckman CEO Resigns As Company Faces Regulatory Challenges

Beckman Coulter announced the resignation of Scott Garrett as chairman, president and CEO Sept. 7 as the firm tries to recover from a recent FDA-triggered diagnostic test market withdrawal and ongoing regulatory scrutiny

Beckman CEO Resigns As Company Faces Regulatory Challenges

Beckman Coulter announced the resignation of Scott Garrett as chairman, president and CEO Sept. 7 as the firm tries to recover from a recent FDA-triggered diagnostic test market withdrawal and ongoing regulatory scrutiny

AdvaMed Begets "AdvaMed Dx" For IVD-Focused Lobbying Effort

AdvaMed is forming an "association within an association" to focus exclusively on in vitro diagnostics, the group announced Dec. 17

Table

View full table

Topics

Tags:
Medical Device
Latest Headlines

NWW: Studies Back Nevro Pain Treatment, FTC Blesses Resonetics Nitinol Deal, Genetic Test Identifies Best RDN Patients

Getting Personal With Tom Miller: CEO Turned VC On Ethical Bets In Diagnostics

Postmarket Surveillance Continues To Challenge AI/ML Device Regulators

Q&A: Allyson Mullen On ‘Uncharted Waters’ Of Breakthrough Pathway

See All
UsernamePublicRestriction

Register

MT028315

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By